Month: July 2020

Phase 1 clinical trial evaluating the off-the-shelf anti-BCMA CAR T candidate CYAD-211 for the treatment of relapsed/refractory multiple myeloma (r/r MM) expected to begin by year-end 2020CYAD-211 represents the company’s first allogeneic CAR T clinical candidate using shRNA technologyMONT-SAINT-GUIBERT, Belgium, July 14, 2020 (GLOBE NEWSWIRE) — Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company’s Investigational New Drug (IND) application for CYAD-211, the company’s first-in-class short hairpin RNA (shRNA)-based allogeneic CAR T candidate and second non-gene edited off-the-shelf program, is in effect with the U.S. Food and Drug Administration (FDA). The...

WISeKey Receives Best IoT Semiconductor Innovator Global 2020 AwardGeneva, Switzerland – July 14, 2020 – WISeKey International Holding Ltd (“WISeKey”, SIX: WIHN / Nasdaq: WKEY), a leading global cybersecurity and IoT company today announced that it was recognized by CFI.co, a print journal and online resource reporting on business, economics, and finance, with the “Best IoT Semiconductor Innovator Global 2020” award.Each year, CFI.co seeks out individuals and organisations that contribute significantly to the convergence of economies and truly add value for all stakeholders.  This year, CFI.co judges have conferred WISeKey the award for Best IoT Semiconductor Innovator Global 2020.Highlights of the judging panel’s findings include:  Operating at the leading edge of the digitalised world, WISeKey is engineering a hack-proof yet user-friendly...

Pratteln, Switzerland, July 14, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces the closing of the first tranche in the amount of CHF 7.5 million nominal in its CHF 20 million financing transaction with a fund managed by Highbridge Capital Management, LLC, as previously announced on June 4, 2020.Also, 3.87 million shares out of Santhera’s conditional share capital for financings are being formally listed on the SIX Swiss Exchange as per July 14, 2020.About SantheraSanthera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. Santhera is building a Duchenne muscular dystrophy (DMD) product portfolio to treat patients irrespective of causative mutations, disease...

Pratteln, Schweiz, 14. Juli 2020 – Santhera Pharmaceuticals (SIX: SANN) gibt den Abschluss der ersten Tranche in Höhe von nominal CHF 7.5 Millionen der am 4. Juni 2020 angekündigten Finanzierungstransaktion von insgesamt CHF 20 Millionen mit einem von Highbridge Capital Management, LLC, verwalteten Fonds bekannt.Ausserdem werden 3.87 Millionen Aktien aus dem bedingten Aktienkapital von Santhera für Finanzierungen per 14. Juli 2020 formell an der SIX Swiss Exchange kotiert.Über SantheraSanthera Pharmaceuticals (SIX: SANN), ein Schweizer Spezialitätenpharmaunternehmen, ist auf die Entwicklung und Vermarktung innovativer Medikamente für seltene neuromuskuläre und pulmonale Erkrankungen mit hohem medizinischem Bedarf fokussiert. Santhera baut ein Duchenne-Muskeldystrophie (DMD) Produktportfolio zur Behandlung von Patienten unabhängig...

ENSPRYNG® est le premier et le seul médicament homologué en Suisse pour le traitement des Troubles du Spectre de la Neuromyélite Optique (NMOSD) chez les patients porteurs d’anticorps contre l’aquaporine-4.Les NMOSD sont un groupe de maladies auto-immunes rares, chroniques et inflammatoires du système nerveux central qui causent des dommages graves principalement au nerf optique et à la moelle épinière pouvant entraîner des handicaps cumulés irréversibles tels que la cécité et l’incapacité de marcher.Bâle, le 14 juillet 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) a annoncé aujourd’hui l’homologation par Swissmedic (Institut suisse des produits thérapeutiques) d’ENSPRYNG® (Satralizumab) pour l’utilisation en monothérapie ou en association avec un traitement immunosuppresseur (IST) pour le traitement des Troubles du Spectre de la Neuromyélite...

ENSPRYNG® ist das erste und einzige in der Schweiz zugelassene Medikament zur Behandlung von Neuromyelitis-Optica-Spektrum-Erkrankungen (NMOSD) bei Patienten die Antikörper gegen Aquaporin 4 aufweisen.NMOSD sind eine Gruppe seltener, chronisch entzündlicher Autoimmunerkrankungen des zentralen Nervensystems, die folgenschwere Schäden vorwiegend am Sehnerv und am Rückenmark verursachen und zu irreversiblen kumulativen Behinderungen wie Blindheit und Gehunfähigkeit führen können.Basel, 14. Juli 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) hat heute bekannt gegeben, dass Swissmedic (Schweizerische Heilmittelinstitut) die Zulassung für ENSPRYNG® (Satralizumab) als Monotherapie oder in Kombination mit einer immunsuppressiven Therapie (IST) zur Behandlung von Neuromyelitis-Optica-Spektrum-Erkrankungen (NMOSD) bei Erwachsenen und Jugendlichen, die...

(Oslo, Norway, 14 July 2020) StrongPoint ASA (StrongPoint, OSE: STRONG) reported revenues of NOK 287.9 million in the second quarter of 2020, up from NOK 287.1 million in the same quarter in 2019. The EBITDA improved to NOK 25.6 million (22.1). StrongPoint’s Retail Technology business area continued a strong performance in the quarter despite volume effects, primarily in Spain and the Baltics, from the COVID-19-situation.“This second quarter and most of this first half of 2020 has obviously been turbulent. Whilst our primary objective has been safeguarding employees, customers and business partners, we have in parallel done our upmost to deliver our business critical products and services to our customers. Focusing on serving the resilient grocery retail market, we have both mobilized our work force and served our customers in ways...

In the second quarter of 2020, AS LHV Group earned EUR 3.6 million in consolidated net profit. AS LHV Pank earned EUR 2.8 million and AS LHV Varahaldus EUR 1 million as net profit.Compared to the first quarter of this year, the net profit of the consolidation group decreased by EUR 3.9 million or by 53%. Compared to the second quarter of 2019, net profit remained lower by EUR 4.1 million or 54%. The return on equity of LHV Group was 5.7% in the second quarter. The results of otherwise successful quarter were influenced primarily by the loan impairments in the amount of EUR 7.7 million made because of the emergency situation and effects of COVID-19.In Q2, the volume of assets of LHV Group grew to EUR 3.7 billion. During the quarter the Group’s consolidated loan portfolio increased by EUR 65 million to EUR 1.8 billion (+4%; +52 million...

Roche will obtain co-development and co-commercialisation rights for pralsetinib, an investigational, precision therapy in late-stage development for people with RET-altered non-small cell lung cancer, various types of thyroid cancer and other solid tumours.Blueprint Medicines and Roche will collaborate on the development of pralsetinib.Roche and Blueprint Medicines will co-commercialise pralsetinib in the US while Roche will be responsible for commercial activities outside the US, excluding Greater China*.Roche will pay an upfront of $675 million in cash in addition to a $100 million equity investment in Blueprint Medicines who is eligible to receive up to $927 million in potential milestones, plus royalties on net product sales outside the US.             Basel, 14 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) and Blueprint Medicines...

2020. aasta II kvartalis teenis AS LHV Group konsolideeritult kokku 3,6 miljonit eurot puhaskasumit. AS LHV Pank teenis 2,8 miljonit eurot puhaskasumit ja AS LHV Varahaldus 1 miljonit eurot puhaskasumit.Võrreldes aasta esimese kvartaliga vähenes konsolideerimisgrupi puhaskasum 3,9 miljoni euro ehk 53% võrra ning võrreldes 2019. aasta II kvartaliga 4,1 miljoni euro võrra ehk 54%. Grupi omakapitali tootluseks kujunes 5,7%. Muus osas eduka kvartali tulemusi mõjutasid eelkõige koroonaviirusest tingitud eriolukorra tõttu tehtud laenude allahindlused summas 7,7 miljonit eurot.LHV Groupi varade maht suurenes II kvartalis 3,7 miljardi euroni. Grupi konsolideeritud laenuportfell kasvas kvartaliga 65 miljoni euro võrra 1,8 miljardi euroni (+4%; +52 miljonit eurot I kvartalis) ning konsolideeritud hoiused suurenesid 134 miljoni euro võrra 3,09 miljardi...